ImageneBio to Participate in Leerink Global Healthcare Conference

Rhea-AI Summary

ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11. Management will join a fireside chat on March 10 at 3:00 PM EST and hold one-on-one meetings. A webcast will be available and archived for 90 days on the company events page.

News Market Reaction – IMA

+1.64%

1 alert

+1.64% News Effect

On the day this news was published, IMA gained 1.64%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 8–11, 2026 Fireside chat date: Tuesday, March 10 Fireside time: 3:00 PM EST +1 more

4 metrics

Conference dates March 8–11, 2026 Leerink Global Healthcare Conference timing

Fireside chat date Tuesday, March 10 ImageneBio scheduled presentation date

Fireside time 3:00 PM EST Scheduled time for ImageneBio’s fireside chat

Webcast archive period 90 days Duration webcast remains available on IR events page

Market Reality Check

Price: $6.37 Vol: Volume 9,119 is about 0.1...

low vol

$6.37 Last Close

Volume Volume 9,119 is about 0.18x the 20-day average of 49,654, indicating muted pre-news activity. low

Technical Shares at $6.72 are trading below the 200-day MA of $8.77, and well under the $18.00 52-week high.

Peers on Argus

Biotech peers show mixed moves: declines in ANRO -1.55% and ARMP -14.40%, while ...

1 Down

Biotech peers show mixed moves: declines in ANRO -1.55% and ARMP -14.40%, while ATOS +0.95%, TCRX +0.91%, and VTGN +4.27% are higher, suggesting stock-specific rather than sector-wide drivers.

Historical Context

3 past events · Latest: Feb 10 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Executive appointment	Positive	-0.9%	Named new Chief Medical Officer to lead clinical organization and ADAPTIVE trial.
Nov 12	Earnings & program update	Positive	-0.7%	Reported Q3 results, cash of $142.6M, $75M placement, and IMG-007 progress.
Nov 06	Investor conferences	Neutral	+2.1%	Announced participation in multiple Q4 2025 investor conferences with webcasts.

Pattern Detected

Recent corporate and financing news has sometimes seen negative price reactions, even when developments appeared strategically positive.

Recent Company History

Over the last several months, ImageneBio has focused on rebuilding its platform and visibility. On Nov 12, 2025, it reported Q3 2025 results, highlighted $142.6M in cash after a reverse merger and $75.0M private placement, and emphasized IMG-007 clinical progress. An earlier Nov 6, 2025 update outlined participation in multiple investor conferences. On Feb 10, 2026, the company appointed Dr. Ben Porter-Brown as Chief Medical Officer to drive the Phase 2b ADAPTIVE trial. Today’s conference appearance continues that investor outreach trajectory.

Market Pulse Summary

This announcement highlights ImageneBio’s participation in a major healthcare conference, with a fir...

Analysis

This announcement highlights ImageneBio’s participation in a major healthcare conference, with a fireside chat on March 10 at 3:00 PM EST and a webcast archived for 90 days. It continues a pattern of investor outreach following Q3 2025 results, financing, and management changes. Regulatory filings have recently covered share resales and board/CMO transitions. Investors may focus on how management communicates progress on the IMG-007 program and the Phase 2b ADAPTIVE trial at this event.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida.

Fireside Date: Tuesday, March 10
Time: 3:00pm EST
Webcast: Linked here and archived for 90 days on events page on the Imagene IR website

About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.

Investor and Media Contact:
ir@imagenebio.com

FAQ

When will ImageneBio (IMA) present at the 2026 Leerink Global Healthcare Conference?

ImageneBio will present in a fireside chat on March 10, 2026 at 3:00 PM EST. According to Imagene, management will also hold one-on-one meetings during the March 8-11 conference in Miami to engage with investors and analysts.

How can investors watch the ImageneBio (IMA) fireside chat webcast on March 10, 2026?

The fireside chat will be webcast live and archived for 90 days on the company's events page. According to Imagene, viewers can access the live stream via the company's investor relations website and replay the archived webcast for three months.

Will ImageneBio (IMA) hold meetings with investors at the Leerink conference March 8-11, 2026?

Yes; management will hold one-on-one investor meetings during the March 8-11 conference. According to Imagene, these meetings are planned alongside the March 10 fireside chat to discuss corporate updates and answer investor and analyst questions.

What time and date is the ImageneBio (IMA) fireside chat at the Leerink conference?

The fireside chat is scheduled for Tuesday, March 10, 2026 at 3:00 PM EST. According to Imagene, the session is part of the company’s participation in the March 8-11 Leerink Global Healthcare Conference in Miami.

Where will the ImageneBio (IMA) webcast be archived and for how long after March 10, 2026?

The webcast will be archived on Imagene's investor events page for 90 days after the live presentation. According to Imagene, investors can replay the archived webcast via the company's events page on its investor relations website for three months.